Results 11 to 20 of about 348,699 (383)

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

Acta Dermato-Venereologica, 2021
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort
Lieneke F.M. Ariëns, Daphne S. Bakker, Lotte S. Spekhorst, Jorien van der Schaft, Judith L. Thijs, Inge Haeck, Annebeth E. Flinterman, Marijke Kamsteeg, Marie L.A. Schuttelaar, Marjolein S. De Bruin-Weller   +9 more
doaj   +1 more source

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

JAMA dermatology, 2021
Key Points Question Are the efficacy and safety of oral upadacitinib superior to subcutaneous dupilumab in adults with moderate-to-severe atopic dermatitis (AD)?
A. Blauvelt, H. Teixeira, E. Simpson, A. Costanzo, M. D. de Bruin‐Weller, S. Barbarot, V. Prajapati, P. Lio, Xiaofei Hu, Tianshuang Wu, John Liu, B. Ladizinski, A. Chu, K. Eyerich   +13 more
semanticscholar   +1 more source

Oral food challenges in children [PDF]

Korean Journal of Pediatrics, 2011
Many patients assume that allergic reactions against foods are responsible for triggering or worsening their allergic symptoms. Therefore, it is important to identify patients who would benefit from an elimination diet, while avoiding unnecessary dietary
Hye Yung Yum, Hyeon Jong Yang, Kyung Won Kim, Tae Won Song, Woo Kyung Kim, Jung Hee Kim, Kang Mo Ahn, Hyun Hee Kim, Soo Young Lee, Bok Yang Pyun   +9 more
doaj   +1 more source

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

Clinical and Translational Allergy, 2023
Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten, Judith Thijs, Marlot van derWal, Chantal vanLuijk, Matthijs vanLuin, Mohsin el Amrani, Edward Knol, Eveline Delemarre, Constance den Hartog Jager, Marlies deGraaf, Daphne Bakker, Joke deBoer, Femke vanWijk, Marjolein deBruin‐Weller   +13 more
doaj   +1 more source

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

New England Journal of Medicine, 2021
BACKGROUND The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies,
T. Bieber, E. Simpson, J. Silverberg, D. Thaçi, C. Paul, A. Pink, Y. Kataoka, C. Chu, M. Dibonaventura, R. Rojo, J. Antinew, I. Ionita, R. Sinclair, S. Forman, Jacek Zdybski, P. Biswas, B. Malhotra, Fan Zhang, H. Valdez   +18 more
semanticscholar   +1 more source

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

JAMA dermatology, 2022
This analysis of 2 randomized clinical trials evaluates long-term (52 weeks) efficacy and safety of upadacitinib treatment in patients with atopic dermatitis.
E. Simpson, K. Papp, A. Blauvelt, C. Chu, H. Hong, N. Katoh, B. Calimlim, J. Thyssen, A. Chiou, R. Bissonnette, L. S. Stein Gold, C. Wegzyn, Xiaofei Hu, Meng Liu, John Liu, A. Tenorio, A. Chu, E. Guttman‐Yassky   +17 more
semanticscholar   +1 more source

Prevalence of Isotretinoin Therapy in Adolescents and Young Adults With and Without Atopic Dermatitis: A Nationwide Prescription-based Population Study

Acta Dermato-Venereologica, 2023
Although isotretinoin has anti-inflammatory and immunomodulatory properties, it can exacerbate atopic dermatitis. National estimates of the extent to which patients with atopic dermatitis are affected by severe acne and isotretinoin tolerability are ...
Cathrine H. Mohn, Hege S. Blix, Anja Maria Brænd, Per Nafstad, Jon Anders Halvorsen   +4 more
doaj   +1 more source

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]

, 2020
Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos, Baldrich, Esther Serra, Herráez, L., Jáuregui, Ignacio, Martín-Santiago, Ana, Ortiz de Frutos, Javier, Sastre, Joaquin, Silvestre, Juan Francisco, Universitat Autònoma de Barcelona, Valero, Antonio   +9 more
core   +3 more sources

Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan

Acta Dermato-Venereologica, 2021
Atopic dermatitis has a substantial impact on work and activity impairment according to studies from Western communities. Prospective studies of work productivity and activity impairment in Asian patients with atopic dermatitis are lacking.
Tom C. Chan, Yi-Chun Lin, Yung-Tsu Cho, Chao-Hsiun Tang, Chia-Yu Chu   +4 more
doaj   +1 more source

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

British Journal of Dermatology, 2020
Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and
A. Wollenberg, A. Blauvelt, E. Guttman‐Yassky, M. Worm, C. Lynde, J. Lacour, L. Spelman, N. Katoh, H. Saeki, Yves Poulin, A. Lesiak, L. Kircik, S. H. Cho, P. Herranz, M. Cork, Ketty Peris, L. Steffensen, B. Bang, A. Kuznetsova, T. N. Jensen, M. L. Østerdal, E. Simpson   +21 more
semanticscholar   +1 more source